BRCA1 induces major energetic metabolism reprogramming in breast cancer cells

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Privat, Maud ^a   Radosevic Robin, Nina ^a   Aubel, Corinne ^a   Cayre, Anne ^a   Penault Llorca, Frédérique ^a   Marceau, Geoffroy ^c   Sapin, Vincent ^c   Bignon, Yves Jean ^a   Morvan, Daniel ^a,b  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b INRA and University of Auvergne   (France)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A; BRCA1 PROTEIN; FATTY ACID; KETONE BODY; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; TRICARBOXYLIC ACID; TUMOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CELL METABOLISM; CITRIC ACID CYCLE; ENZYME REGULATION; GENETIC TRANSCRIPTION; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; METABOLITE; OXIDATIVE PHOSPHORYLATION; BIOSYNTHESIS; BREAST TUMOR; ENERGY METABOLISM; FEMALE; GENETICS; METABOLISM; MITOCHONDRION; PATHOLOGY; TUMOR CELL LINE;

BRCA1 PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; CITRIC ACID CYCLE; ENERGY METABOLISM; FEMALE; GLYCOLYSIS; HUMANS; MITOCHONDRIA; NEOPLASM PROTEINS; OXIDATIVE PHOSPHORYLATION;

EID: 84904175466     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102438     Document Type: Article

References (45)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71. (Pubitemid 24345325)
2. Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4: 665-676. (Pubitemid 39215065)
3. Yarden RI, Papa MZ (2006) BRCA1 at the crossroad of multiple cellular pathways: approaches for therapeutic interventions. Mol Cancer Ther 5: 1396-1404. (Pubitemid 44070475)
4. Xiang T, Ohashi A, Huang Y, Pandita TK, Ludwig T, et al. (2008) Negative Regulation of AKT Activation by BRCA1. Cancer Res 68: 10040-10044.
5. Kang HJ, Kim HJ, Rih JK, Mattson TL, Kim KW, et al. (2006) BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression. J Biol Chem 281: 13047-13056. (Pubitemid 43855214)
6. van der Groep P, Bouter A, Menko FH, van der Wall E, van Diest PJ (2008) High frequency of HIF-1alpha overexpression in BRCA1 related breast cancer. Breast Cancer Res Treat 111: 475-480.
7. Moreau K, Dizin E, Ray H, Luquain C, Lefai E, et al. (2006) BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem 281: 3172-3181. (Pubitemid 43845927)
8. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
9. Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
10. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11: 85-95.
11. Thompson CB (2009) Metabolic enzymes as oncogenes or tumor suppressors. N Engl J Med 360: 813-815.
12. Pasini B, Stratakis CA (2009) SDH mutations in tumorigenesis and inherited endocrine tumours: lesson from the phaeochromocytoma-paraganglioma syndromes. J Intern Med 266: 19-42.
13. King A, Selak MA, Gottlieb E (2006) Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 25: 4675-4682. (Pubitemid 44187617)
14. Niemann S, Muller U (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26: 268-270.
15. Kaelin WG Jr (2009) SDH5 mutations and familial paraganglioma: somewhere Warburg is smiling. Cancer Cell 16: 180-182.
16. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360: 765-773.
17. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321: 1807-1812.
18. Morvan D, Demidem A (2007) Metabolomics by proton nuclear magnetic resonance spectroscopy of the response to chloroethylnitrosourea reveals drug efficacy and tumor adaptive metabolic pathways. Cancer Res 2007 Mar 1; 67(5): 2150-9. (Pubitemid 46424234)
19. Bayet-Robert M, Morvan D (2013) Metabolomics reveals metabolic targets and biphasic responses in breast cancer cells treated by curcumin alone and in association with docetaxel. PLoS One 2013; 8(3): e57971 doi:101371/ journalpone0057971 Epub 2013 Mar 5.
20. Bae I, Fan S, Meng Q, Rih JK, Kim HJ, et al. (2004) BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res 64: 7893-7909. (Pubitemid 39446923)
21. Cao L, Xu X, Cao LL, Wang RH, Coumoul X, et al. (2007) Absence of full-length Brca1 sensitizes mice to oxidative stress and carcinogen-induced tumorigenesis in the esophagus and forestomach. Carcinogenesis 28: 1401-1407. (Pubitemid 47241788)
22. Nam H, Chung BC, Kim Y, Lee K, Lee D (2009) Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification. Bioinformatics 25: 3151-3157.
23. Ippolito JE, Xu J, Jain S, Moulder K, Mennerick S, et al. (2005) An integrated functional genomics and metabolomics approach for defining poor prognosis in human neuroendocrine cancers. Proc Natl Acad Sci U S A 102: 9901-9906. (Pubitemid 40993665)
24. Privat M, Aubel C, Arnould S, Communal Y, Ferrara M, et al. (2009) Breast cancer cell response to genistein is conditioned by BRCA1 mutations. Biochem Biophys Res Commun 379: 785-789.
25. Bayet-Robert M, Loiseau D, Rio P, Demidem A, Barthomeuf C, et al. (2010) Quantitative two-dimensional HRMAS 1H-NMR spectroscopy-based metabolite profiling of human cancer cell lines and response to chemotherapy. Magn Reson Med 2010 May; 63(5): 1172-83 doi:101002/mrm22303.
26. Elstrodt F, Hollestelle A, Nagel JH, Gorin M, Wasielewski M, et al. (2006) BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res 66: 41-45. (Pubitemid 43166006)
27. Gottlieb E, Tomlinson IP (2005) Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 5: 857-866. (Pubitemid 41746030)
28. Reitman ZJ, Yan H (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 2010 Jul 7; 102(13): 932-41 doi:101093/jnci/djq187 Epub 2010 May 31.
29. Robey RB, Hay N (2009) Is Akt the "Warburg kinase"?-Akt-energy metabolism interactions and oncogenesis. Semin Cancer Biol 19: 25-31.
30. Xu B, Kim S, Kastan MB (2001) Involvement of Brca1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol 21: 3445-3450. (Pubitemid 32381780)
31. Chautard E, Loubeau G, Tchirkov A, Chassagne J, Vermot-Desroches C, et al. (2010) Akt signaling pathway: a target for radiosensitizing human malignant glioma. Neuro Oncol 2010 May; 12(5): 434-43 doi:101093/neuonc/nop059 Epub 2010 Feb 4.
32. Mathupala SP, Ko YH, Pedersen PL (2009) Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol 19: 17-24.
33. Scatena R, Bottoni P, Pontoglio A, Mastrototaro L, Giardina B (2008) Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs 17: 1533-1545.
34. Vander Heiden MG (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10: 671-684.
35. Seo M, Kim JD, Neau D, Sehgal I, Lee YH (2011) Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect. PLoS One 6: e24179.
36. Xiang T, Jia Y, Sherris D, Li S, Wang H, et al. (2011) Targeting the Akt/mTOR pathway in Brca1-deficient cancers. Oncogene 30: 2443-2450.
37. Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, et al. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 7: 77-85. (Pubitemid 40126384)
38. Pollard PJ, Briere JJ, Alam NA, Barwell J, Barclay E, et al. (2005) Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum Mol Genet 14: 2231-2239. (Pubitemid 41418022)
39. Semenza GL, Roth PH, Fang HM, Wang GL (1994) Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269: 23757-23763. (Pubitemid 24293585)
40. Shaw RJ (2006) Glucose metabolism and cancer. Curr Opin Cell Biol 18: 598-608.
41. Magnard C, Bachelier R, Vincent A, Jaquinod M, Kieffer S, et al. (2002) BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. Oncogene 21: 6729-6739. (Pubitemid 35221915)
42. Brunet J, Vazquez-Martin A, Colomer R, Grana-Suarez B, Martin-Castillo B, et al. (2008) BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer. Mol Carcinog 47: 157-163. (Pubitemid 351231444)
43. Delikatny EJ, Chawla S, Leung DJ, Poptani H (2011) MR-visible lipids and the tumor microenvironment. NMR Biomed 24: 592-611.
44. Fan S, Meng Q, Saha T, Sarkar FH, Rosen EM (2009) Low concentrations of diindolylmethane, a metabolite of indole-3-carbinol, protect against oxidative stress in a BRCA1-dependent manner. Cancer Res 69: 6083-6091.
45. Warburg O (1956) On the origin of cancer cells. Science 123: 309-314.